NewGen BioPharma Corp. (NEWG)

[DaReal]

A/S increased to 300M shares per NVSOS Filing

Previous Stock Value:
Par Value Shares: 75,000,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 75,000.00

New Stock Value:
Par Value Shares: 300,000,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 300,000.00

http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=Khquk4Zw0j%252b7L421uY5zzA%253d%253d&CorpName=NEWGEN+BIOPHARMA+CORP.

[Renee]

Greenwind Nrg, Inc., GRWD, changed to NewGen BioPharma Corp., NEWG:

http://otce.finra.org/DLSymbolNameChanges

[Big Brother]

Missed this LOI for a reverse merger a couple weeks ago, shell has only traded a total of about 5K shares in it's history.

http://newgenbiopharma.com/

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11661948

Founder & Chairman of NewGen BioPharma Corp.

Dr. Jaikaria Founded NewGen BioPharma Corp., US and its Indian subsidiary, New India BioPharma in 2010. Dr. Jaikaria has successfully raised multi-million dollars in investment capital and has transformed NewGen into a commercial stage company with a marketed product and a strong pipeline of products in various stages of clinical and pre-clinical development. NewGen BioPharma Corporation is a specialty pharma company that is developing and commercializing enhanced pharmaceuticals through reformulating approved products using proprietary Micellar Nano Particulate [MNP] technology platform. The MNP platform improves the solubility and bioavailability of difficult to formulate and deliver drugs that have low water solubility and poor bioavailability.

MNP platform is one of the three nanotechnology platforms that have a drug approved by the FDA. Nano-formulations confer significant advantages to drugs leading to an improvement in their bioavailability in the blood, improvement in safety, efficacy, dosage reductions and elimination of fed-fast variability – all leading to improved clinical outcomes and better patient compliance. In addition MNP platform can deliver traditional drugs delivered as oral pills through the skin. A striking attribute of the topical MNP preparations is that the residence time of the Active Pharmaceutical Ingredient (API) is increased in the skin, thereby reducing the dose or reducing the number of applications per day. This attribute also makes MNP technology very desirable to address a huge unmet medical need – to deliver drugs effectively and selectively to the skin or in a local manner to joints etc. We also have an entire line of MNP based cosmeceutical products that are desirable in the current market place.